Characterization of Fatty Acid Profiles in Infants With Intestinal Failure-Associated Liver Disease.

Autor: Baker MA; Vascular Biology Program and Department of Surgery, Boston Children's Hospital, Boston, Massachusetts, USA., Mitchell PD; Institutional Centers for Clinical and Translational Research, Boston Children's Hospital, Boston, Massachusetts, USA., O'Loughlin AA; Vascular Biology Program and Department of Surgery, Boston Children's Hospital, Boston, Massachusetts, USA., Potemkin AK; Vascular Biology Program and Department of Surgery, Boston Children's Hospital, Boston, Massachusetts, USA., Anez-Bustillos L; Vascular Biology Program and Department of Surgery, Boston Children's Hospital, Boston, Massachusetts, USA., Dao DT; Vascular Biology Program and Department of Surgery, Boston Children's Hospital, Boston, Massachusetts, USA., Fell GL; Vascular Biology Program and Department of Surgery, Boston Children's Hospital, Boston, Massachusetts, USA., Gura KM; Department of Pharmacy, Boston Children's Hospital, Boston, MA, USA., Puder M; Vascular Biology Program and Department of Surgery, Boston Children's Hospital, Boston, Massachusetts, USA.
Jazyk: angličtina
Zdroj: JPEN. Journal of parenteral and enteral nutrition [JPEN J Parenter Enteral Nutr] 2018 Jan; Vol. 42 (1), pp. 71-77. Date of Electronic Publication: 2017 Dec 06.
DOI: 10.1002/jpen.1026
Abstrakt: Background: The purpose of this study was to characterize fatty acid profiles (FAPs) in parenteral nutrition (PN)-dependent infants with intestinal failure-associated liver disease (IFALD) receiving soybean oil-based lipid emulsion (SO) doses of ∼3 and ∼1 g/kg/d.
Methods: Prospectively collected data were retrospectively reviewed. Serum FAPs of patients <1 year old who experienced development of IFALD while receiving standard PN with SO were examined before transitioning to a fish oil-based lipid emulsion for IFALD treatment. Time on SO, dose, gestational age, and weight- and length-for-age z scores were also reviewed.
Results: Among the 49 patients analyzed, there were no differences in demographics or anthropometrics between patients who received standard SO (SO-S) (n = 14, range of dosage 2.06-3.31 g/kg/d) and reduced SO (SO-R) (n = 35, range of dosage 0.90-1.34 g/kg/d). Patients received SO for a median of 53 days (interquartile range 39, 73) before FAP measurement. Patients who received SO-R had significantly higher Mead acid and lower α-linolenic, eicosapentaenoic, linoleic, stearic, total ω-3, and total ω-6 fatty acid levels than patients who received SO-S (P < .01). Triene:tetraene ratios were higher in patients who received SO-R (P = .0009), and no patients experienced biochemical essential fatty acid deficiency (EFAD).
Conclusion: PN-dependent infants with IFALD receiving SO-R have different FAPs than patients receiving SO-S. No patients in either group had biochemical EFAD.
(© 2017 American Society for Parenteral and Enteral Nutrition.)
Databáze: MEDLINE
Externí odkaz: